Jan M. Hanneken

Washington University in St. Louis

Papers

1

Total Citations

19

H-Index

1

About

Dr. Jan M. Hanneken is a leading urologic oncologist whose research focuses on the intersection of immunotherapy and surgical management for advanced kidney cancer. Her most impactful work, a 2020 study on elective cytoreductive nephrectomy following checkpoint inhibitor immunotherapy, has garnered 19 citations and fundamentally reshaped treatment paradigms for patients with initially unresectable metastatic clear cell renal cell carcinoma. By demonstrating that immunotherapy can render previously inoperable tumors amenable to surgery, Dr. Hanneken has pioneered a critical bridge between systemic therapy and surgical intervention, offering new hope for patients with advanced disease. Her contributions extend beyond this landmark paper, as she actively investigates how to optimize patient selection and timing for nephrectomy in the immunotherapy era. Through her clinical research, Dr. Hanneken has established herself as a key figure in the evolving landscape of renal cell carcinoma management, where her work directly translates into improved survival outcomes and quality of life for patients facing this challenging diagnosis.

Research Focus

Key Achievements

1
H-Index
1
Papers
19
Total Citations
19
Avg Citations/Paper
🏆 Most Cited Paper
Elective Cytoreductive Nephrectomy After Checkpoint Inhibitor Immunotherapy in Patients With Initially Unresectable Metastatic Clear Cell Renal Cell Carcinoma
19 citations · 2020
📈 Most Prolific Year: 2020 (1 Papers)
🤝 Key Collaborators: 8
🏛 Institutions: Washington University in St. Louis

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago